Navigation Links
Perle BioScience Selects BlazeFund As Its Crowd Funding Platform
Date:9/4/2013

BOSTON, Sept. 4, 2013 /PRNewswire/ -- BlazeFund, a new equity crowd funding company in Boston, Massachusetts, has listed the first biotech company on their platform. Atlanta-based Perle BioScience is a life sciences company whose mission is to address patient needs that have been considered "impossible" to tackle.

(Logo: http://photos.prnewswire.com/prnh/20130808/CG60459LOGO)

Perle BioScience's founder, Dr. Claresa Levetan, is internationally recognized as a leader of diabetes research. She previously co-founded CureDM and was a lead inventor of a therapeutic drug for the reversal of diabetes. CureDM's IP portfolio was licensed to Sanofi in 2010 for upfront and commercial milestone payments of a potential value totaling $335M.

Dr. Levetan is raising capital for Perle BioScience to "pave the way for a revolutionary therapeutic treatment which will create a transformational shift in the treatment of diabetes," states Dr. Levetan. According to the American Diabetes Association, there are currently 26 million diabetes patients in the US.

Dr. Levetan indicates, "Nearly 1 out of 10 healthcare dollars or 4 out of 10 Medicare dollars are spent on patients with diabetes. As health care costs are spiraling and the diabetes population is growing, Perle BioScience is looking to address the underlying mechanisms that cause diabetes. Our treatment will be a huge benefit to society as a whole – not just for diabetic patients - but also in terms of managing healthcare costs."

Perle BioScience elected to utilize equity crowd funding to obtain the company's growth capital. Dr. Levetan mentions, "Perle is making a paradigm shift in the treatment of diabetes, and
'/>"/>

SOURCE BlazeFund
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. 150,000 Medical Professionals Stay Paperless with Practice Fusion
2. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
3. Whats New with Flu this Season: Industry Recommendations, New Vaccines and 100% Paperless Flu Program Solution
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
6. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
7. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
8. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
9. Sangamo BioSciences to Acquire Ceregene
10. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
11. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel, Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... developing octreotide capsules for the orphan condition acromegaly, ... ended June 30, 2015 and provided a corporate ... been a transformative time for Chiasma, as we ... announced that our first New Drug Application (NDA) ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
(Date:8/31/2015)... NEW YORK , Aug. 31, 2015  Dipexium ... company focused on the development and commercialization of Locilex® ... peptide, today announced plans to participate in four investor ... September 2, 2015 at the Sidoti & Company, LLC ... City . David P. Luci , President ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... YORK, July 8, 2011 The U.S. Food and ... Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for ... for active booster immunization against tetanus, diphtheria and pertussis ... vaccine approved for use in this age group.  With ...
... July 8, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... of multifunctional medical and industrial products, is pleased to ... Up to a 35% discount will be offered in ... promotional activity range from infrared thermometers , digital ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Enjoy Only One Thermometer in Various Domains 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nurse Scholar-in Residence at the Institute of Medicine (IOM) of the National Academies. ... at Columbia University School of Nursing. A member of the Institute of Medicine ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... 1,500 investor-families have received permanent green cards (I-829 petition approval) from the USCIS ... petition is the final step of the EB-5 visa process for immigrant investors ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Situations ... seldom arise at the most convenient time for everyone involved. These occasions highlight ... , Universal Translation Services has real people available to handle any ...
(Date:9/1/2015)... Las Vegas, NV (PRWEB) , ... September 01, ... ... home care or Self-Directed Care is, how to access caregivers and what to ... of other valuable and pertinent information. , Founded in 2006 in Canoga Park, ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2
... Echo Therapeutics,Inc. (OTC Bulletin Board: ECTE), a ... had completed an approximately,$2.3 million private financing with ... and certain other select institutional and strategic,investors of ... $2,292,459 in aggregate principal amount of Senior Convertible,Notes ...
... Ehmke,Manufacturing Company of Philadelphia was among the ... 23 industry partners, customers and,individuals Feb. 12 ... received the Innovative Business Performer of the ... zone, small business,category. The award recognizes large, ...
... Corporation,(Nasdaq: VOLC ), a leading provider of intravascular ... the diagnosis and,treatment of coronary and peripheral vascular disease, ... 2007., For the quarter ended December 31, 2007, ... the company, and a 35 percent increase,over revenues of ...
... PT ... -, SAN JOSE, ... Board: PDXC), a provider of,veterinary primary care and specialized services to companion animals,today ... 20th Annual OC Growth Stock Conference on Wednesday,February 20 at 8:30 a.m. Pacific ...
... Breast Cancer Survivors , Breast cancer survivors, ... death from non-cancer causes than from breast cancer. ... are surviving longer, and many are dying of ... and colleagues with the National Cancer Institute of ...
... spread, researchers say , , TUESDAY, Feb. 12 (HealthDay News) -- ... ductal carcinoma in situ (DCIS) are highly anxious about their ... recurrence or of developing invasive breast cancer, a new study ... they,re waiting for the other shoe to drop," said lead ...
Cached Medicine News:Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Defense Logistics Agency Recognizes Ehmke Manufacturing Company 2Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 2Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 3Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 4Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 5Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 6Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 7Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 8Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 9Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 10Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 11Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 12Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 13Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 14Health News:Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent 15Health News:Pet DRx to Present at Roth 20th Annual OC Growth Stock Conference 2Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Precancerous Breast Lesions Cause Unnecessary Worry 2Health News:Precancerous Breast Lesions Cause Unnecessary Worry 3Health News:Precancerous Breast Lesions Cause Unnecessary Worry 4
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: